Search

Tamsulosin

[Label] Other alpha-1 adrenoceptor antagonists developed in the 1980s were less selective and more likely to act on the smooth muscle of blood vessels, resulting in hypotension. … [Label] Antagonism of these receptors leads to relaxation of smooth muscle in the prostate and detrusor muscles in the bladder, allowing for better urinary flow.

Iron sucrose

Due to less side effects than iron dextran, iron sucrose is more preferred in chronic kidney disease patients. … Iron sucrose (sucroferric oxyhydroxide or iron saccharate) is used as a source of iron in patients with iron deficiency anemia with chronic kidney disease (CKD), including those who are undergoing dialysis

Tapentadol

[A260721, A36596] Tapentadol was first approved by the FDA on November 20, 2008. The extended-release formulation of tapentadol was also approved by the FDA on August 26, 2011. … [L47291] Used in the management of pain, tapentadol is typically reserved for patients who have limited alternative treatment options.

Citrus bioflavonoids

Pancrelipase

[L2510] For further information on the components of this mixture please visit [DB11065], [DB11066] and [DB13147]. … [L2509] The pancrelipase mixture was developed by Ortho-McNeil-Janssen Pharmaceuticals, Inc and FDA approved on April 12, 2010.

Piperacillin

It is also used in combination with other antibiotics.

Ferrous ascorbate

Anidulafungin

Anidulafungin or Eraxis is an anti-fungal drug manufactured by Pfizer that gained approval by the Food and Drug Administration (FDA) in February 21, 2006; it was previously known as LY303366.

Hyoscyamine

[A228423] It is commonly extracted from plants in the _Solanaceae_ or nightshade family.[A228423] Research into the action of hyoscyamine in published literature dates back to 1826. … [L31548,L31553] Although hyoscyamine is marketed in the United States, it is not FDA approved.[L31548,L31553]

Ganirelix

[L43045] The first case of pregnancy achieved after the use of ganirelix in an assisted reproduction program was reported in 1998.[A252195] Ganirelix was first approved by the FDA on July 29, 1999. … Ganirelix is indicated for controlled ovarian hyperstimulation in assisted reproduction techniques.